Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy. - Chikagawa Y; Higashi D; Sakai S; Yoshino H; Nukii Y; Mura H; Nakagawa S; Yamada S; Yoroidaka T; Imi T; Zaimoku Y; Maruyama H; et al. (International journal of hematology, 2026)